CSF2 and pulmonary alveolar proteinosis: The recommended treatment options for PAP with clinical symptoms mainly include WLL, emerging therapies based on pathogenesis (such as recombinant human GM-CSF therapy, rituximab, plasma exchange, etc.), and lung transplantation (1).